Media stories about Zoetis (NYSE:ZTS) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zoetis earned a daily sentiment score of 0.21 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.0052017913589 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Zoetis Inc (ZTS) to Post FY2018 Earnings of $3.00 Per Share, Gabelli Forecasts (americanbankingnews.com)
- Investors In Zoetis Inc (NYSE:ZTS) Are Paying Above The Intrinsic Value (finance.yahoo.com)
- Zoetis (ZTS) Price Target Increased to $78.00 by Analysts at BMO Capital Markets (americanbankingnews.com)
- Zoetis (ZTS) Rating Reiterated by BMO Capital Markets (americanbankingnews.com)
- Zoetis (ZTS) Downgraded by Zacks Investment Research to Hold (americanbankingnews.com)
Zoetis (NYSE:ZTS) opened at $74.59 on Friday. The company has a market capitalization of $36,350.00, a P/E ratio of 39.26, a PEG ratio of 1.91 and a beta of 1.06. Zoetis has a fifty-two week low of $52.00 and a fifty-two week high of $75.47. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be given a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a yield of 0.68%. This is an increase from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date of this dividend is Thursday, January 18th. Zoetis’s dividend payout ratio is 22.11%.
A number of equities research analysts have recently commented on ZTS shares. BidaskClub downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 20th. Cantor Fitzgerald reissued a “buy” rating and set a $75.00 price target on shares of Zoetis in a research report on Tuesday, September 26th. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a research report on Thursday, October 12th. Stifel Nicolaus restated a “buy” rating and set a $65.00 price objective on shares of Zoetis in a research note on Tuesday, October 24th. Finally, BMO Capital Markets set a $65.00 price objective on Zoetis and gave the stock a “hold” rating in a research note on Wednesday, October 25th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the stock. Zoetis currently has an average rating of “Buy” and a consensus price target of $71.28.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.